The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

Statement of Discontinuation of the study	
Name of Company: GlaxoSmithKline	
Study No: 112980 (EudraCT#2009-012460-14)	
Product: GSK357941A;SB210602;SB217744	
Title : A phase II, open-label, randomised study to assess the safety and immunogenicity of a birth dose of GSK Biologicals' reduced-antigen-content tri-component pertussis vaccine followed by routine paediatric vaccination at 2, 4, 6 and 12-18 months of age, and to explore the ability of this schedule to accelerate the acquisition of pertussis antibodies.	
Phase: II	
Study Period: April 2010 To August 2012	
Centres: NA	
Number of Subjects:0	
Publications: NA	
Statement on discontinuation of the study: Discontinued by GlaxoSmithKline during preparation of the trial. No patient entered the study, therefore no results / data are available.	